flavivirus
major
caus
infecti
diseas
human
dengu
viru
caus
estim
million
case
febril
ill
year
includ
increas
number
case
hemorrhag
fever
west
nile
viru
recent
spread
mediterranean
basin
western
hemispher
caus
thousand
sporad
case
enceph
annual
despit
exist
licens
vaccin
yellow
fever
japanes
enceph
tickborn
enceph
also
claim
mani
thousand
victim
year
across
vast
endem
area
antivir
therapi
could
potenti
reduc
morbid
mortal
flaviviru
infect
effect
drug
current
avail
articl
introduc
collect
paper
antivir
research
molecular
target
flaviviru
antivir
drug
design
murin
model
dengu
viru
diseas
aim
encourag
drug
develop
effort
review
flaviviru
replic
cycl
discuss
envelop
glycoprotein
proteas
helicas
methyltransferas
rnadepend
rna
polymeras
potenti
drug
target
special
attent
given
viral
proteas
viral
protein
subject
individu
articl
journal
togeth
paper
highlight
current
statu
drug
discoveri
effort
flaviviru
diseas
suggest
promis
area
research
articl
introduc
collect
paper
antivir
research
focus
target
flaviviru
drug
discoveri
recogn
import
flavivirus
agent
human
diseas
urgent
need
develop
new
vaccin
effect
therapi
genu
flaviviru
contain
member
includ
yellow
fever
yf
dengu
den
west
nile
wn
japanes
enceph
je
tickborn
enceph
tbe
gubler
although
licens
vaccin
avail
yfv
jev
tbe
mackenzi
et
al
none
develop
flavivir
diseas
effort
vaccin
develop
dengu
continu
challeng
decad
main
issu
inabl
vaccin
protect
simultan
four
antigen
distinct
serotyp
barrier
vaccin
develop
sporad
natur
infect
caus
agent
wnv
jev
tbev
could
complet
prevent
carri
univers
immun
across
huge
geograph
region
absenc
vaccin
drug
specif
therapi
need
antivir
medic
approv
use
flavivirus
ribavirin
suppress
replic
agent
vitro
demonstr
vivo
activ
limit
rodent
model
leyssen
et
al
thu
need
new
antivir
reduc
viremia
earli
stage
infect
block
viral
replic
brain
case
enceph
modul
host
respons
prevent
treat
diseas
bray
articl
begin
describ
flavivir
replic
cycl
briefli
summar
role
viral
protein
entri
replic
assembl
matur
potenti
drug
target
five
paper
examin
protein
much
greater
detail
one
describ
individu
step
process
matur
envelop
e
glycoprotein
show
could
potenti
block
smallmolecul
drug
perera
et
al
anoth
describ
novel
approach
develop
antihelicas
compound
lescar
et
al
two
differ
activ
protein
consid
therapeut
target
methyltransferas
dong
et
al
rnadepend
rna
polymeras
malet
et
al
fifth
paper
review
current
statu
mous
model
develop
dengu
fever
dengu
hemorrhag
fevershock
syndrom
yauch
shestra
matur
flaviviru
virion
smooth
spheric
diamet
genom
packag
viral
capsid
protein
c
hostderiv
lipid
bilay
copi
envelop
protein
e
embed
mukhopadhyay
et
al
e
protein
initi
complex
precursor
membran
protein
prm
assembl
virion
endoplasm
reticulum
form
immatur
particl
immatur
particl
transport
transgolgi
compart
undergo
matur
cellular
serin
proteas
furin
mediat
cleavag
prm
result
homodimer
e
protein
form
fusioncompet
matur
particl
releas
circul
stiasni
heinz
singlestrand
positivesens
rna
genom
contain
singl
long
open
read
frame
flank
untransl
region
secondari
structur
essenti
initi
translat
replic
figur
lindenbach
et
al
end
genom
type
cap
end
lack
polya
tail
translat
genom
host
cell
machineri
produc
polyprotein
compris
viral
structur
nonstructur
protein
requir
replic
assembl
new
virion
host
cell
flavivir
infect
includ
monocyt
macrophag
dendrit
cell
marianneau
et
al
tassaneetrithep
et
al
barbaspaeth
et
al
lozach
et
al
krishnan
et
al
viru
attach
cell
surfac
mediat
e
protein
enter
cell
receptormedi
endocytosi
figur
low
ph
endosom
compart
trigger
fusion
viral
host
cell
membran
mediat
structur
reorgan
e
lead
releas
nucleocapsid
viral
rna
cytoplasm
translat
rna
gener
polyprotein
cotransl
posttransl
process
virusencod
serin
proteas
hostencod
proteas
includ
signalas
furin
produc
structur
protein
nonstructur
protein
order
cprme
rice
et
al
kda
kda
best
character
nonstructur
protein
multipl
enzym
activ
requir
viral
replic
three
distinct
activ
serin
proteas
togeth
cofactor
requir
polyprotein
process
helicasentpas
activ
requir
unwind
doublestrand
replic
form
rna
rna
triphosphatas
requir
cap
nascent
viral
rna
falgout
et
al
zhang
l
et
al
aria
et
al
li
h
et
al
benarroch
et
al
mutat
affect
activ
impair
viral
replic
matusan
et
al
b
largest
highli
conserv
flavivir
protein
greater
sequenc
ident
across
den
serotyp
contain
two
distinct
enzymat
activ
separ
interdomain
region
sadenosyl
methyltransferas
sam
egloff
et
al
rnadepend
rna
polymeras
rdrp
chu
westaway
tan
et
al
ackermann
padmanabhan
guyatt
et
al
kda
requir
flaviviru
replic
presum
involv
negativestrand
synthesi
unknown
mechan
larg
delet
yfv
abolish
viral
replic
complement
tran
function
express
sindbi
viru
vector
lindenbach
rice
furthermor
temperaturesensit
mutat
defect
viral
replic
fail
accumul
neg
strand
rna
function
c
suggest
requir
neg
strand
rna
synthesi
muylaert
et
al
kda
small
hydrophob
transmembran
protein
involv
gener
virusinduc
membran
viru
assembl
leung
kda
integr
membran
protein
may
induc
membran
rearrang
form
viral
replic
complex
miller
et
al
roosenda
et
al
kda
inhibit
type
interferon
respons
host
cell
munozjordan
et
al
may
modul
viral
replic
via
interact
umareddi
et
al
viral
rna
replic
occur
rough
endoplasm
reticulum
er
golgideriv
membran
call
vesicl
packet
vp
chu
westaway
mackenzi
nonstructur
protein
dsrna
concentr
vp
constitut
site
viral
rna
synthesi
mackenzi
et
al
westaway
et
al
westaway
et
al
newli
synthes
viral
rna
extrud
intermembran
space
doublemembran
vp
exit
cytoplasm
unknown
mechan
uchil
satchidanandam
assembl
viru
particl
occur
lumen
rough
er
first
step
process
coat
newli
synthes
viral
rna
c
protein
khromykh
westaway
see
also
perera
et
al
volum
next
e
prm
heterodimer
envelop
nucleocapsid
form
immatur
viru
particl
bud
rer
lumen
golgi
mackenzi
westway
howev
mechan
interact
c
protein
within
nucleocapsid
still
clear
matur
viru
particl
occur
transgolgi
network
prm
cleav
furin
along
conform
rearrang
e
mukhopadhyay
et
al
essenti
step
viru
transit
fusionincompet
noninfecti
viru
particl
matur
fusioncompet
infecti
virion
matur
particl
eventu
exit
host
cell
exocytosi
identif
small
molecul
specif
inhibit
critic
step
viral
life
cycl
requir
detail
biochem
structur
character
essenti
viral
protein
develop
high
throughput
screen
assay
includ
biochem
assay
cellular
assay
also
essenti
step
leadfind
process
type
assay
pro
con
although
vitro
assay
targetspecif
util
avail
structur
inform
optim
inhibitor
test
cell
alway
risk
activ
compound
unabl
penetr
cellular
membran
cellular
assay
obviat
issu
target
deconvolut
labori
process
interest
lead
compound
identifi
next
stage
test
physiolog
relev
small
anim
model
review
yauch
shreshta
discuss
current
statu
develop
mous
model
dengu
dengu
hf
rodent
model
also
avail
wn
yf
je
viral
infect
charlier
et
al
holbrook
gowen
describ
viral
c
prm
e
protein
undergo
number
conform
chang
entri
assembl
exit
viral
particl
cours
matur
chang
potenti
offer
target
inhibit
antivir
drug
c
proteinth
highli
basic
kda
c
protein
interact
viral
genom
rna
form
nucleocapsid
nc
minim
function
region
requir
dimer
viru
assembl
character
jone
et
al
patkar
et
al
capsid
protein
compris
intern
hydrophob
sequenc
mediat
membran
associ
et
al
capsid
fold
dimer
monom
contain
four
alpha
helic
n
c
termini
contain
charg
residu
ctermin
region
may
involv
rna
associ
et
al
wang
et
al
dimer
c
induc
interact
dna
rna
kiermayr
et
al
develop
vitro
assembl
system
would
use
identifi
compound
block
capsid
dimer
capsidrna
interact
could
lead
identif
inhibitor
block
either
step
glycosyl
precursor
protein
prm
process
polyprotein
er
host
signalas
cleavag
capsidprm
site
nterminu
prme
site
carboxi
terminu
associ
prm
e
produc
noninfecti
immatur
viru
particl
arrang
prm
prme
heterodim
immatur
particl
protect
fusion
loop
e
protein
prematur
fusion
immatur
particl
transit
low
ph
environ
golgi
compart
revers
conformationalmorpholog
chang
occur
e
protein
prior
process
prm
cleavag
prm
cellular
serin
proteas
furin
transgolgi
network
result
irrevers
conform
chang
e
peptid
cleav
prm
pr
retain
virion
releas
virion
secret
expos
neutral
ph
thu
protect
e
protein
prematur
fusion
kda
e
protein
matur
dimer
form
major
surfac
compon
virion
form
e
protein
compet
cell
surfac
attach
fusion
viru
entri
host
cell
describ
perera
et
al
viru
entri
follow
endosom
acidif
induc
structur
chang
e
rearrang
homodim
neutral
ph
homotrim
acid
ph
allison
et
al
stiasni
et
al
stiasni
heinz
fusion
loop
dii
domain
buri
didiii
pocket
expos
fusogen
state
e
trimer
prior
insert
host
cell
membran
drug
discoveri
point
view
develop
robust
highthroughput
assay
base
proteinprotein
interact
would
use
screen
conform
transit
prm
e
perera
et
al
review
recent
advanc
understand
dynam
flaviviru
e
protein
suggest
three
region
within
protein
could
target
antivir
ligand
bind
pocket
eprotein
raft
matur
viru
e
homotrim
avail
structur
inform
immatur
matur
particl
thu
pave
way
ration
drug
design
proteasewithin
ntermin
amino
acid
residu
protein
identifi
includ
trypsinlik
serin
proteas
domain
catalyt
triad
residu
asp
ser
sequenc
comparison
fletterick
gorbalenya
et
al
use
vitro
transcript
translat
precursor
protein
contain
proteas
domain
well
polyprotein
precursor
express
recombin
vaccinia
viru
vector
establish
cleavag
proteas
sensit
site
ci
tran
ciscleavag
perform
heterodimer
complex
chamber
et
al
preugschat
et
al
wengler
et
falgout
et
al
zhang
l
et
al
clum
et
al
viral
proteas
prefer
two
basic
amino
acid
residu
argarg
argli
ly
arg
occasion
glnarg
posit
preced
cleavag
site
follow
gli
ala
ser
posit
chamber
et
al
sinc
polyprotein
process
prerequisit
assembl
viral
replicas
complex
viral
proteas
repres
attract
therapeut
target
integr
membran
protein
clum
et
al
coloc
within
distinct
paracrystallin
convolut
membran
structur
suggest
may
site
polyprotein
process
westaway
et
al
hydrophob
region
like
requir
membran
associ
polyprotein
precursor
render
proteas
sensit
site
optim
context
cisand
transcleavag
vitro
proteas
assay
use
proteas
precursor
demonstr
cotransl
insert
exogen
ad
canin
pancreat
microsom
membran
requir
effici
ci
cleavag
site
vitro
contain
hydrophob
domain
flank
conserv
hydrophil
region
amino
acid
residu
delet
three
hydrophob
region
abrog
membran
requir
cleavag
vitro
suggest
ci
cleavag
site
vitro
hydrophob
region
dispens
clum
et
al
precursor
devoid
hydrophob
region
contain
conserv
hydrophil
domain
link
proteas
domain
carboxi
termin
region
contain
cleavag
site
express
e
coli
precursor
express
insolubl
inclus
bodi
purifi
denatur
refold
purifi
protein
activ
cleav
methioninelabel
nter
precursor
well
fluorogen
peptid
substrat
tbutyloxycarbonyl
boc
coumarin
amc
yusof
et
al
kinet
paramet
substrat
specif
proteas
report
khumthong
et
al
khumthong
et
al
chanprapaph
et
al
recent
shown
shorten
linker
five
amino
acid
residu
ctermin
region
hydrphil
domain
yield
solubl
noncoval
associ
heterodimer
wnv
proteas
activ
cleav
fluorogen
peptid
substrat
bocglylysargamc
mueller
et
al
leung
et
al
show
linker
cofactor
hydrophil
region
proteas
domain
could
substitut
linker
precursor
could
express
e
coli
activ
proteas
solubl
noncleav
form
thu
obviat
denatur
refold
step
purif
proteas
leung
et
al
use
activ
noncleav
form
wnv
proteas
number
group
report
substrat
specif
kinet
paramet
profil
peptidebas
viral
proteas
inhibitor
suitabl
enzymat
substrat
identifi
function
profil
use
tetra
peptid
octapeptid
librari
compris
substrat
li
j
et
al
detail
specif
studi
led
design
robust
screen
assay
highthroughput
format
employ
colorimetr
fluoresc
readout
nall
et
al
li
j
et
al
chappel
et
al
gouvea
et
al
knox
et
al
lohr
et
al
radichev
et
al
shiryaev
et
al
shiryaev
et
al
b
c
yin
et
al
b
studi
util
truncat
contain
domain
alon
bera
et
al
recent
report
character
biochem
properti
wnv
proteas
hydrophil
domain
full
length
connect
noncleav
glyrich
linker
describ
author
identifi
two
autolyt
intramolecular
cleavag
site
one
site
rapid
occur
protein
purif
wherea
cleavag
second
site
arg
locat
within
ctermin
rna
helicas
region
slower
studi
taken
togeth
reveal
proteas
activ
requir
cleavag
site
free
nterminu
proteas
domain
leung
et
al
bera
et
al
crystal
structur
noncleav
form
wnv
proteas
glyrich
linker
amino
acid
residu
hydrophil
domain
wnv
proteas
domain
solv
erbel
et
al
subsequ
second
crystal
structur
wnv
proteas
report
bovin
pancreat
trypsin
inhibitor
replac
tetrapeptid
substratebas
inhibitor
use
solv
first
structur
aleshin
et
al
presenc
cofactor
wnv
proteas
domain
complex
peptid
inhibitor
reveal
direct
interact
activ
site
cterminu
wnv
wrap
around
involv
format
pocket
erbel
et
al
interact
proteas
inhibitor
result
induc
fit
conform
activ
site
contrast
interact
substrat
bind
site
absenc
inhibitor
suggest
crystal
structur
noncleav
form
cofactor
peptid
link
glyrich
linker
erbel
et
al
one
challeng
foreseen
develop
activesit
serineproteas
inhibitor
identifi
compound
block
viral
enzym
host
serin
proteas
recent
studi
previous
describ
vitro
proteas
assay
yusof
et
al
mueller
et
al
adapt
highthroughput
format
use
wnv
strain
proteas
express
purifi
e
coli
screen
compound
wnv
proteas
compound
identifi
inhibit
proteas
activ
use
substrat
bocglylysargamc
rang
select
criteria
appli
activ
ii
molecular
weight
dalton
iii
calcul
valu
logarithm
octanolwat
partit
coeffici
c
lop
p
iv
sum
nitrogen
oxygen
atom
hbond
acceptor
v
hbond
donor
atom
vi
rotat
bond
final
contain
peptidelik
eg
nhco
bond
would
mimic
proteas
substrat
appli
criteria
compound
select
cluster
three
core
structur
five
group
base
related
chemic
structur
among
limit
number
compound
select
character
core
structur
contain
quinolin
deriv
differ
substitut
found
activ
ki
valu
compound
b
wnv
proteas
respect
wherea
less
effect
assay
perform
proteas
prefer
substrat
bocglyargargamc
respect
compound
cytotox
vero
cell
wider
rang
drug
concentr
test
wherea
compound
b
moder
cytotox
compound
b
assay
inhibit
wnv
replic
vero
cell
infect
viruslik
particl
contain
wnv
replicon
encod
renilla
luciferas
report
pierson
et
al
system
wnv
replicon
rna
encod
report
deliv
cytoplasm
infect
cell
viruslik
particl
initi
cascad
event
translat
polyprotein
process
assembl
viral
replicas
complex
viral
rna
replic
system
use
assay
effect
inhibitor
step
sinc
inhibitor
viral
proteas
expect
interfer
polyprotein
process
earli
step
affect
subsequ
step
potenc
could
assess
precis
monitor
report
gene
express
function
inhibitor
concentr
use
system
compound
b
found
inhibit
wnv
replic
valu
select
index
kinet
analysi
molecular
dock
studi
indic
compound
b
bind
near
substrat
bind
site
thu
inhibit
activ
enzym
work
crystal
structur
proteas
complex
inhibitor
necessari
better
understand
mode
inhibit
class
compound
optim
identifi
potent
inhibitor
mueller
et
al
mueller
et
al
press
recent
use
ht
approach
differ
class
inhibitor
compound
identifi
nation
institut
health
compound
librari
johnston
et
al
kinet
analysi
hit
show
uncompetit
inhibitor
wnv
author
conclud
identifi
compound
seem
interfer
function
interact
cofactor
domain
johnston
et
al
lescar
et
al
flavivir
rna
helicas
domain
locat
follow
domain
within
ctermin
threefouth
contain
conserv
motif
associ
superfamili
class
ntpase
rna
helicas
helicas
activ
thought
requir
melt
secondari
structur
prior
initi
rna
synthesi
resolv
rna
duplex
either
separ
dsrna
intermedi
form
viral
rna
synthesi
translocas
remov
protein
bound
viral
rna
strand
separ
energydepend
reaction
driven
atp
hydrolysi
therefor
rna
helicas
atpas
activ
activ
flavivir
rna
helicas
hydrolyz
nonspecif
nucleosid
triphosph
henc
known
ntpase
purin
prefer
pyrimidin
nucleosid
triphosph
activ
stimul
addit
singlestrand
polyribonucleotid
li
et
al
suzich
et
al
tamura
et
al
warren
et
al
conserv
posit
charg
motif
rkrk
modul
rnastimul
ntpase
rna
helicas
rna
triphosphatas
activ
mutagenesi
four
basic
residu
abolish
rnastimul
ntpase
activ
although
basal
ntpase
activ
still
retain
bind
singlestrand
rna
also
abolish
well
rna
bind
depend
activ
rna
triphosphatas
rna
helicas
affect
mutagenesi
basic
amino
acid
residu
li
h
et
al
yon
et
al
mutat
critic
residu
abolish
helicas
activ
prevent
viral
replic
matusan
et
al
drug
target
unwind
activ
could
act
way
inhibit
atpas
activ
interf
atp
bind
hydrolysi
prevent
nucleic
acid
bind
block
unwind
steric
hinder
transloc
helicas
flavivir
helicas
challeng
target
drug
develop
nonstructur
protein
mainli
mechan
action
well
understood
also
problem
select
compound
inhibit
via
atp
bind
site
compound
like
cytotox
host
technic
level
tradit
assay
screen
helicas
time
consum
new
assay
use
dna
substrat
recent
develop
highthroughput
format
frick
option
avail
assay
use
rna
substrat
crystal
structur
helicas
domain
report
den
yf
je
virus
wu
et
al
xu
et
al
yamashita
rna
bind
tunnel
locat
center
surround
residu
eman
three
domain
recent
structur
fulllength
protein
proteas
helicas
domain
report
kunjin
base
sax
analysi
mastrangelo
et
al
viru
luo
et
al
latter
first
report
structur
flaviviru
full
length
protein
sever
compound
identifi
rna
helicas
inhibitor
flaviand
rna
virus
borowski
et
al
carta
et
al
frick
johansson
et
al
maga
et
al
wu
et
al
xi
borowski
et
al
report
wnv
helicas
inhibitor
also
activ
cellular
assay
ic
halogen
benztriol
also
shown
inhibit
wnv
helicas
borowski
et
al
recent
ringexpand
nucleosid
ren
also
report
inhibit
jev
wnv
helicas
zhang
n
et
al
b
report
inhibitor
target
ntpase
activ
mutat
studi
sampath
et
al
show
residu
helicas
activ
atpas
mutant
lead
question
whether
target
alloster
site
pocket
line
rna
bind
tunnel
would
better
altern
dong
et
al
flavivir
mtase
recent
studi
enzym
appear
attract
drug
target
four
enzym
activ
requir
nascent
rna
mtase
function
domain
locat
ntermin
region
protein
methyl
posit
guanin
cap
well
ribos
posit
first
transcrib
nucleotid
adenin
gpppam
egloff
et
al
mutat
critic
residu
methyl
activ
impair
viral
replic
indic
enzym
play
essenti
role
viral
replic
cycl
zhou
et
al
interestingli
methyl
guanin
cap
wnv
specif
viral
rna
sequenc
recogn
distinct
element
within
loop
viral
rna
activ
site
methyl
map
tetrad
k
k
e
determin
methyl
although
shown
essenti
activ
zhang
et
al
recent
analyz
four
variant
mutat
viabil
mutant
rnatransfect
cell
genom
sequenc
recov
virion
rna
reveal
two
class
adapt
mutat
first
within
sl
insert
second
within
mtase
polymeras
domain
zhang
b
et
al
result
support
conclus
author
genet
interact
among
mtase
polymeras
sl
replic
adapt
mutat
confer
surviv
fit
mutat
alon
confer
lethal
phenotyp
crystal
structur
wnv
mtase
report
egloff
et
al
zhou
et
al
base
structur
inform
luzhkov
et
al
report
highthroughput
structurebas
virtual
screen
inhibitor
result
identif
novel
inhibitor
first
step
develop
mtase
inhibitor
much
work
remain
done
compound
develop
drug
rnadepend
rna
polymeras
rdrp
human
cell
lack
rnadepend
dna
rna
polymeras
revers
transcriptas
rdrp
flavivirus
class
enzym
appear
one
promis
target
antivir
virus
util
polymeras
replic
therefor
surpris
compound
current
market
us
treatment
viral
infect
polymeras
inhibitor
especi
nucleosid
analog
viral
polymeras
one
two
favorit
target
hcv
drug
therapi
jensen
ascion
liuyoung
kozal
viral
polymeras
activ
target
use
either
nucleosid
analog
nonnucleosid
compound
latter
target
alloster
site
protein
nucleosid
analog
must
phosphoryl
prodrug
convert
activ
form
order
inhibit
enzym
activ
site
one
argument
work
favor
activ
site
inhibitor
therapi
chanc
develop
resist
mutant
lower
compar
alloster
inhibitor
inhibitor
flavivir
rna
replic
character
use
subgenom
rna
replicon
system
barkli
et
al
ng
et
al
infect
assay
kajasterudnitski
et
al
leyssen
et
al
micha
et
al
migliaccio
et
al
paeshuys
et
al
sidwel
et
al
takhampunya
et
al
potenti
use
approach
determin
effect
antivir
compound
vitro
rdrp
assay
employ
lysat
flavivirusinfect
inhibitortr
cell
contain
endogen
replic
viral
rna
associ
viral
replicas
compon
chu
westaway
bartholomeusz
wright
system
fulli
exploit
although
feasibl
demonstr
takhampunya
et
al
second
vitro
rdrp
assay
system
reli
exogen
ad
subgenom
rna
templat
contain
region
includ
cycliz
sequenc
rna
element
infect
cell
lysat
et
al
purifi
protein
tan
et
ackermann
padmanabhan
guyatt
et
al
nomaguchi
et
al
flaviviru
rdrp
capabl
de
novo
rna
synthesi
ackermann
padmanabhan
selisko
et
al
yap
et
al
recent
report
robust
miniatur
assay
highthroughput
compound
screen
vitro
rdrp
assay
system
like
use
studi
mode
action
nucleosid
analog
triphosphoryl
form
de
novo
initi
elong
process
chain
termin
review
malet
et
al
discuss
drug
discoveri
effort
focus
rdrp
emphasi
structur
inform
use
effect
drug
design
crystal
structur
wnv
recent
report
yap
et
al
includ
model
initi
complex
dgtp
bind
site
rdrp
virus
show
typic
righthand
structur
finger
palm
thumb
domain
region
contain
nuclear
local
sequenc
transport
nucleu
also
shown
involv
interact
johannson
et
al
target
interact
context
viral
rna
option
could
explor
vitro
assay
incorpor
protein
viral
polymeras
activ
readout
would
use
identifi
key
replisom
inhibitor
antivir
drug
discoveri
program
prudent
consid
host
cell
compon
potenti
target
virushost
interact
import
viral
life
cycl
also
pathogenesi
flavivirus
like
viral
pathogen
gain
entri
host
specif
interact
viral
protein
host
cell
receptor
strategi
usurp
interact
could
lead
discoveri
candid
antivir
drug
topic
discuss
elegantli
perera
et
al
volum
number
cellular
protein
report
bind
viral
rna
case
disrupt
bind
seem
affect
viral
replic
review
see
brinton
exampl
eukaryot
translat
elong
factor
bind
sl
wnv
rna
rna
blackwel
brinton
de
novaocampo
et
al
mutat
interfer
bind
affect
minu
strand
rna
synthesi
without
effect
translat
viral
rna
davi
et
al
refer
therein
addit
autoantigen
la
protein
polypyrimidin
tract
bind
protein
ptb
also
report
bind
rna
de
novaocampo
et
al
garciamontalvo
et
al
yocupiciomonroy
et
al
moreov
two
member
rna
recognit
motif
famili
rna
bind
protein
cell
intracellular
tiarel
tiar
protein
also
shown
bind
wnv
sl
minu
strand
rna
high
affin
emara
brinton
li
et
al
howev
function
cellular
protein
bind
viral
rna
viru
life
cycl
yet
elucid
thu
identif
function
character
cellular
protein
flaviviru
life
cycl
infanc
review
accompani
paper
demonstr
mani
potenti
molecular
target
antivir
therapeut
flavivirus
howev
base
past
experi
develop
drug
clinic
use
rdrp
may
prove
target
best
chanc
success
enzym
form
part
multimer
complex
play
crucial
role
viral
genom
replic
encod
viral
genom
cellar
counterpart
toxic
issu
malet
et
al
nucleosid
analogu
mimic
natur
ntp
substrat
could
potent
inhibitor
especi
mistakenli
incorpor
newli
synthes
progeni
rna
could
potenti
involv
altern
basepair
interact
replic
yield
lethal
mutat
genom
rna
strategi
ampli
describ
other
literatur
attract
approach
drug
develop
rna
virus
employ
rdrp
replic
cameron
castro
crotti
et
al
graci
et
al
parient
et
al
second
attract
target
drug
develop
viral
proteas
antihiv
proteas
inhibitor
exampl
class
drug
alreadi
clinic
use
compon
highli
activ
antiretrovir
therapi
haart
flaviviru
proteas
might
also
prove
use
target
drug
therapi
although
remain
seen
whether
viral
serin
proteas
suffici
differ
cellular
serin
proteas
furin
also
recogn
two
basic
amino
acid
residu
posit
antiflavivir
proteas
inhibitor
would
pose
toxic
issu
viru
entri
inhibitor
also
offer
attract
choic
antivir
therapeut
fact
class
inhibitor
overcom
problem
associ
classic
inhibitor
proteas
dna
rna
polymeras
cellular
toxic
emerg
drug
resist
viru
entri
inhibitor
develop
approv
antivir
treatment
infect
bridg
cammack
citterio
rusconi
daeleman
et
al
demarco
et
al
kazmierski
et
al
munch
et
al
rusconi
et
al
rna
virus
includ
flavivirus
replic
cytoplasm
evolv
machineri
depend
host
enzym
function
nucleu
requir
viral
replic
dong
et
al
enzym
perform
function
potenti
target
drug
develop
exampl
class
inhibitor
respiratori
syncyti
viral
mrna
viral
rna
depend
rna
polymeras
liuzzi
et
al
bray
et
al
bray
et
al
show
mice
infect
ebola
viru
treat
sadenosyllhomocystein
hydrolas
inhibitor
protect
lethal
inhibit
methyl
rna
helicas
flavivirus
also
novel
target
enzym
multimer
complex
requir
viral
replic
presum
need
unwind
doublestrand
rna
intermedi
genom
replic
describ
detail
lescar
et
al
collect
paper
antivir
research
demonstr
exist
rang
molecular
target
new
antivir
drug
flavivirus
avail
structur
inform
number
essenti
viral
protein
tool
screen
efficaci
inhibitor
provid
new
opportun
ration
drug
design
develop
drug
multipl
novel
target
promis
approach
least
partial
circumv
emerg
drug
resist
new
inhibitor
identifi
import
assess
physicochem
properti
sinc
determin
factor
pharmacokinet
new
drug
candid
initi
stage
lead
find
choic
target
avail
structur
inform
avail
assay
screen
activ
strongli
influenc
success
lead
candid
member
flaviviru
famili
share
similar
replic
strategi
prospect
identifi
broadspectrum
inhibitor
prophylact
therapeut
activ
number
differ
pathogen
flaviviru
replic
cycl
virion
bind
cellsurfac
attach
molecul
receptor
intern
endocytosi
low
ph
endosom
viral
glycoprotein
mediat
fusion
viral
cellular
membran
allow
disassembl
virion
releas
rna
cytoplasm
viral
rna
translat
polyprotein
process
viral
cellular
proteas
viral
nonstructur
protein
replic
genom
rna
virion
assembl
occur
er
membran
capsid
protein
viral
rna
envelop
membran
embed
glycoprotein
form
immatur
viru
particl
transport
secretori
pathway
low
ph
transgolgi
network
tgn
prm
cleav
furin
matur
virion
releas
cytoplasm
see
text
inform
courtesi
rushika
perera
richard
kuhn
